Short Interest in Celularity Inc. (NASDAQ:CELUW) Declines By 60.1%
Short Interest in Celularity Inc. (NASDAQ:CELUW) Declines By 60.1%
Celularity Inc. (NASDAQ:CELUW – Get Rating) was the recipient of a significant decline in short interest in the month of February. As of February 28th, there was short interest totalling 7,300 shares, a decline of 60.1% from the February 13th total of 18,300 shares. Based on an average daily trading volume, of 14,600 shares, the short-interest ratio is currently 0.5 days.
凱魯達公司（NASDAQ：CELUW-獲取評級）在二月份短期利益顯著下降的收件人。截至 2 月 28 日，總共有 7,300 股的短期利息，較 2 月 13 日的 18,300 股股份下降了 60.1%。根據平均每日交易量為 14,600 股，短息比率目前為 0.5 天。
Celularity Trading Up 14.3 %
精度交易上升 14.3%
NASDAQ:CELUW traded up $0.01 during trading hours on Friday, hitting $0.08. 82,509 shares of the company's stock traded hands, compared to its average volume of 17,187. Celularity has a twelve month low of $0.06 and a twelve month high of $1.99. The stock has a fifty day moving average price of $0.09.
納斯達克：CELUW 周五交易時間內上漲 0.01 美元，觸及 0.08 美元。該公司股票交易手中的 82,509 股，相比其平均交易量為 17,187。天然有一個十二個月的低點 0.06 美元和十二個月的高點 1.99 美元。該股票的五十天移動平均價為 0.09 美元。
Celularity Company Profile
卓達公司簡介
(Get Rating)
(取得評分)
Celularity Inc, a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, a placental-derived CAR-T therapy, which is in Phase I clinical trial for the treatment of B-cell malignancies; CYNK-001, placental-derived unmodified natural killer (NK) cell that is in Phase I clinical trial to treat acute myeloid leukemia, as well as in Phase I/IIa clinical trial for the treatment of glioblastoma multiforme and COVID-19; CYNK-101, an allogeneic genetically modified NK cell, which is in Phase I clinical trial to treat HER2+ gastric and gastroesophageal cancers; APPL-001, a placenta-derived mesenchymal-like adherent stromal cell that is in a pre-clinical stage for the treatment of Crohn's disease; and PDA-002, a placenta-derived mesenchymal-like adherent stromal cell, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy.
Celularity Inc 是臨床階段的生物技術公司，開發現成的胎盤衍生異基因細胞療法，用於治療癌症，免疫和傳染病。它通過三個部分進行操作：細胞治療，退行性疾病和生物班王。該公司的主要治療方案包括 CYCART-19，胎盤衍生的 CAR-T 療法，該療法正在治療 B 細胞惡性腫瘤的 I 期臨床試驗中；CYNK-001，胎盤衍生的未修飾天然殺傷劑（NK）細胞，該細胞處於治療急性髓細胞白血病的 I 期臨床試驗中，以及用於治療急性髓細胞白血病的 I/IIA 期臨床試驗中，用於膠質瘤和 COVID-19 多形瘤治療試驗; CYNK-101 是一種異體轉基因 NK 細胞，正處於治療 HER2+ 胃癌和胃食管癌的 I 期臨床試驗中；APPL-001，胎盤-衍生的間充質樣附著劑基質細胞，處於治療克羅恩氏病的臨床前階段；和 PDA-002，胎盤衍生的間葉類粘附劑基質細胞，處於臨床前階段，用於治療面部異位素的肌肉營養不良。
Featured Stories
特色故事
- Get a free copy of the StockNews.com research report on Celularity (CELUW)
- What the SVB Financial Collapse Means for U.S. Banks
- MarketBeat Week in Review – 3/6 – 3/10
- 2 Offshore Drilling Stocks Set to Extract Big Profits
- Three Staples Stocks With Double-Digit Upside Ahead
- Can Investors Trust Consumers to Lift American Outdoor Brands?
- 免費獲取有關天然性研究報告的副本
- SVB 金融崩潰對美國銀行意味著什麼
- 市場節拍週的回顧 — 3/6 — 3/10
- 2 海上鑽探股票將提取巨額利潤
- 前面有兩位數字的三個主要股票
- 投資者可以信任消費者提升美國戶外品牌嗎？
Receive News & Ratings for Celularity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celularity and related companies with MarketBeat.com's FREE daily email newsletter.
接收每日奇魯特的新聞和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件通訊接收 Celularity 和相關公司的最新新聞和分析師評級的簡要每日摘要。